Please login to the form below

Addressing Climate Impact: The Healthcare Paradox

For the healthcare and pharmaceutical industry, the impact of climate change is twofold – responding to the increased risk of certain diseases and conditions and decarbonising their own processes and products to prevent worsening impact.

Andrew Harrison
Managing Director, Hanover Health

For the healthcare and pharmaceutical industry, the impact of climate change is twofold – responding to the increased risk of certain diseases and conditions and decarbonising their own processes and products to prevent worsening impact.

Observable effects of climate change are already being felt – for example, the Lancet’s 2019 report on the infection rates of dengue fever (expressed as vectorial capacity for transmissions) showed that nine of the ten most suitable years for transmission on record since 1950 have occurred since 2000. In 2018 there were 220 million more heatwave exposures affecting older populations increasing risks of heart and kidney stress and disease and stroke.

Yet, paradoxically, developing and delivering solutions to these challenges has a climate cost. Analysis has suggested that combined CO2 emissions from hospitals, health services and medical supply chains across the OECD group of market economies plus China and India comprise 4% of total global emissions footprint – greater than either aviation or shipping.

The NHS has been found to produce 5.4% of England’s total carbon emissions. For healthcare providers, challenges lie in areas such as transport, building efficiency and waste reduction – where high-quality waste products in operating theatres that could be recycled largely end up being labelled as infectious clinical waste and are incinerated at a high financial and environmental cost. Similarly, some procedures are particularly carbon intensive. Hospitals have been exploring solutions ranging from retrofitting heat recovery technology to dialysis machines, to switching operating room anaesthetics, which account for almost a third of the UK’s health and social care sector emissions, to less-polluting gas. Linked options include introducing technology to capture these gases and seeking alternative clinical techniques.

There is a clear role for industry to support healthcare providers through innovative product design. Boehringer Ingelheim recently introduced the first reusable, propellant-free inhaler for patients with asthma and COPD, supporting objectives of carbon and plastic waste reduction. An associated study suggested that the reusability of the inhaler reduces its carbon footprint by as much as 71% and should mean that over a million fewer inhalers are needed annually.

The challenge of producing sustainable medicines is also being explored by the Innovative Medicines Initiative. The scheme represents Europe’s largest public-private partnership in life sciences, between the European Commission and the European pharmaceutical industry. Its €26.m (£21.2m) CHEM21 project brings together six pharmaceutical companies, thirteen universities and four small and mid-sized enterprises from across Europe to develop sustainable biological and chemical alternatives to finite materials, such as precious metals, which are currently used as catalysts in the manufacture of medicines.
To minimise wider environmental impacts, efforts are being made to introduce biotechnology to the manufacturing processes for medicine production.

Nonetheless, it is critical that pharmaceutical companies retain a focus on driving decarbonisation and best practice sustainability in-house as well as in product design. In 2015 the global pharmaceutical industry produced 55% more CO2 than the automotive industry1. The NHS Sustainable Development Unit’s 2018 National Resources Footprint2 stated that pharmaceuticals are the second largest producer of both water footprint and carbon emissions (12.1%) relating to the healthcare service in England.

The shift to a far more rapid rate of decarbonisation across the pharmaceutical industry and the broader healthcare sector will require significant action. But trends have shown that focused efforts can deliver results on decarbonisation, and indeed can be delivered alongside economic growth and expansion of service. In the NHS emissions from health and social care have been cut by 18.5%3 since 2007, despite clinical activity rising by over a quarter over the same period.

Interestingly, the report on global pharmaceutical performance4 demonstrated that the companies leading on emissions (Amgen, Johnson & Johnson and Roche Holding) were also three of the most profitable in the sector. This is clear proof that there is economic opportunity in innovating for the future.

This article was originally published in 'Net Zero Unpacked: An Essential Guide for Business Strategy & Corporate Communications.

The report contains insights from leading companies both inside and outside of the healthcare industry including Novo Nordisk, Apple, Lucozade Ribena Suntory, Facebook, and Sky, on how businesses are acting to support Net Zero.

1 International comparison of health care carbon footprints: Peter-Paul Pichler, Ingram S Jaccard, Ulli Weisz and Helga Weisz,


3 Natural Resource Footprint 2018,

4 IDC FutureScape: Worldwide Datacenter 2019 Predictions,

26th February 2020



Company Details

Hanover Communications

+44 (0)20 7400 4480

Contact Website

Riverside House
Southwark Bridge House
United Kingdom

Latest content on this profile

Will the NHS be safe in Liz Truss’s Hands?
As expected, Liz Truss has been anointed as the new Prime Minister. One of her major challenges is the NHS and, with only two years to another general election, she does not have much time to restore falling public confidence in the service.
Hanover Communications
A new prescription for the U.S. healthcare market?
Last month the U.S. Government passed the Inflation Reduction Act, paving the way for unprecedented drug pricing reforms across the country. In a market with spiralling healthcare costs, and increasing stories of patients missing out, or rationing treatment, the Act is welcomed by many. But it’s also severely criticised by others, including representatives from the pharmaceutical industry who say it jeopardises future innovation and drug discovery. As the largest pharmaceuticals market, the impact of the legislation will be felt outside of the U.S., but what does this look like, in the short and long-term? Is it a proverbial drop in the ocean, or is a storm brewing?
Hanover Communications
What's next for the 'indispensable' health system?
No one is remotely indispensable” – those of the words many of us have heard these past few weeks. As Boris Johnson and the previously incumbent Cabinet are now considering their next moves, where does that leave health policy at one of the most volatile points in recent history? We were set for a bumper few months of hotly anticipated announcements, including the 10-Year Cancer  Plan response, the Women’s Health Strategy, and the implementation plan for the Life Sciences Vision, amongst many others. But what will happen as the forthcoming leadership contest dominates the column inches? How will the Civil Service and NHS stand up to the challenges it faces without certainty of who is steering the ship? We will explore some of the possibilities of what will happen next, and most importantly, how we in communications can support the health system at such a critical time post-pandemic. To find out, read the latest blog on the PM Hub, penned by Hanover Health's Senior Account Director Ursula Ritz.
Hanover Communications
How can the UK be a catalyst for change in women’s health? 
Women’s health has once again been thrust to the fore, with almost daily stories on hormone replacement therapy (HRT) supply shortages in the UK providing us with a stark reminder of the challenges women are facing in this country every day. The good news is, the UK Government is making a genuine and concerted effort to tackle women’s health issues, having set out its Vision for women’s health in December, and a full Strategy due to be published imminently. We have a real opportunity to change women’s experience of healthcare for the better, but we cannot afford to get this wrong. In her latest blog, Hanover’s Georgia Hunt explores how the upcoming Women’s Health Strategy should address the concerns of women today and improve the lives of the women of tomorrow.
Hanover Communications
Innovative contracting at the top of the market access agenda
Value-based contracting (VBC) is firmly on the market access agenda across Europe and there are converging views on what is needed in this space.  Pharma and biotech, patients, payers, regulators and HTA agencies gathered at the World Evidence, Pricing and Access Congress in March to discuss challenges and potential solutions. Hanover hosted a discussion about experiences of VBC and where changes are needed. We explored whether a global archetype approach could support in-country negotiating agreements.   In their latest blog, Hanover Health’s Emma Eatwell and Josie Godfrey explore what the future for VBC might look like.
Hanover Communications
The future of nanomedicine regulation
With the EU’s upcoming revision of the general pharmaceutical legislation, the bloc has the chance to provide long-awaited clarity around the future of nanomedicine. And just as important, it will give the EU a chance to lead on a conversation around the needed regulatory framework for nanomedicines as other countries -including the US- currently struggle with this. In their latest blog, Hanover Brussels Alicia Rojo Santos and Pilar Serrano explores why the sector expecting to set off following the success of the Pfizer and Moderna SARS-CoV-2 vaccines is more important than ever.
Hanover Communications